Get the Stockscreener App
5.32
0.75%
0.00
Alpha Cognition Inc stock is traded at $5.32, with a volume of 2,246.
It is up +0.75% in the last 24 hours and down -10.67% over the past month.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
See More
Previous Close:
$5.32
Open:
$5.26
24h Volume:
2,246
Relative Volume:
0.03
Market Cap:
$115.23M
Revenue:
$7.43M
Net Income/Loss:
$-19.47M
P/E Ratio:
-3.8926
EPS:
-1.3667
Net Cash Flow:
$-16.02M
1W Performance:
-8.22%
1M Performance:
-10.67%
6M Performance:
-24.29%
1Y Performance:
-2.90%
1-Day Range:
$5.26
$5.48
1-Week Range:
$5.25
$6.1899
52-Week Range:
$3.75
$11.54
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
5.30 | 115.67M | 7.43M | -19.47M | -16.02M | -1.3667 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | H.C. Wainwright | Buy |
Alpha Cognition Inc Stock (ACOG) Latest News
Earnings Scheduled For March 26, 2026 - Benzinga
Opaleye Management Inc. Increases Stake in Alpha Cognition Inc. - GuruFocus
Alpha Cognition (ACOG) to Release Earnings on Monday - MarketBeat
If You Invested $1,000 in Alpha Cognition (ACOG) - Stock Titan
Major Investor Quietly Boosts Stake in Alpha Cognition Inc., Signaling Growing Confidence - TipRanks
Opaleye boosts Alpha Cognition (ACOG) stake with open‑market buys - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Alpha Cognition (ACOG) holder Opaleye adds 1,331 common shares - Stock Titan
Stock Analysis: Is Inhibrx Biosciences Inc a turnaround story2026 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
Alpha Cognition Inc. (NASDAQ:ACOG) Sees Significant Growth in Short Interest - MarketBeat
Major Investor Quietly Boosts Position in Alpha Cognition Inc. - TipRanks
Opaleye boosts Alpha Cognition (ACOG) stake with open-market share buys - Stock Titan
ALPHA COGNITION INC (NASDAQ: ACOG) announced that the company plans to release its financial results for the fourth quarter and full year of 2025 on Thursday, March 26, 2026. - Bitget
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 - The Joplin Globe
Opaleye adds Alpha Cognition (ACOG) shares in open-market purchases - Stock Titan
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences - Business Wire
History Review: Can Alpha Cognition Inc. continue delivering strong returns2026 Price Targets & Low Drawdown Momentum Ideas - baoquankhu1.vn
Major Investor Quietly Ramps Up Stake in Alpha Cognition - TipRanks
Major Investor Quietly Boosts Its Stake in This Emerging Biotech Player - TipRanks
Market Wrap: Can Alpha Cognition Inc deliver consistent dividendsJuly 2025 Big Picture & Safe Capital Allocation Plans - baoquankhu1.vn
ACOG SEC FilingsAlpha Cognition 10-K, 10-Q, 8-K Forms - Stock Titan
Opaleye Management reports 11.00% stake in Alpha Cognition (ACOG) - Stock Titan
Major Investor Quietly Boosts Position in Emerging Biotech Player - TipRanks
Opaleye boosts Alpha Cognition (ACOG) stake with open-market buys - Stock Titan
Alpha Cognition Inc. (NASDAQ:ACOG) Short Interest Down 32.1% in February - Defense World
Alpha Cognition (FRA:7N70) Cyclically Adjusted Price-to-FCF : (As of Mar. 01, 2026) - GuruFocus
Alpha Cognition (FRA:7N70) Cyclically Adjusted PB Ratio : (As of Feb. 28, 2026) - GuruFocus
Opaleye Management Inc. Expands Stake in Alpha Cognition Inc. - GuruFocus
Block Trades: Will Alpha Cognition Inc outperform during market ralliesPortfolio Update Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Is Alpha Cognition Inc. a strong candidate for buy and holdTrade Entry Report & Low Risk High Win Rate Stock Picks - mfd.ru
ACOG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG) and Fulcrum Therapeutics (FULC) - The Globe and Mail
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study - BioSpace
Alpha Cognition announces first patient enrolled in Beacon real-world effectiveness study - marketscreener.com
Major Investor Makes Bold Move on Alpha Cognition Stock - TipRanks
Opaleye lifts Alpha Cognition (ACOG) stake with 171,410-share purchase - Stock Titan
ACOGAlpha Cognition Latest Stock News & Market Updates - Stock Titan
Opaleye entities report 2.19M shares in Alpha Cognition (ACOG) filing - Stock Titan
Opaleye, James Silverman report 2.27M ACOG shares (10.43%) (ACOG) - Stock Titan
Alpha Cognition secures patent for Alzheimer’s drug dosing regimens By Investing.com - Investing.com Canada
Alpha Cognition secures patent for Alzheimer’s drug dosing regimens - Investing.com Australia
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens - BioSpace
Alpha Cognition Gets US Patent for Administration of Alzheimer's Treatment - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Several Insiders Invested In Alpha Cognition Flagging Positive News - Yahoo Finance
Highs Report: Will Hancock Whitney Corporation benefit from rising consumer demandWeekly Loss Report & Consistent Growth Stock Picks - baoquankhu1.vn
How interest rate cuts could boost Alpha Cognition Inc. stockJuly 2025 Rallies & Community Trade Idea Sharing Platform - mfd.ru
Should I buy Alpha Cognition Inc. stock nowTrade Entry Report & Community Supported Trade Ideas - mfd.ru
Will Alpha Cognition Inc. stock continue upward momentum2025 AllTime Highs & Risk Controlled Stock Pick Alerts - mfd.ru
Alpha Cognition (NASDAQ:ACOG) Trading Up 13.3%Here's What Happened - MarketBeat
Setup Watch: Can Alpha Cognition Inc sustain its profitabilityWeekly Trade Review & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Cognition Inc Stock (ACOG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Mar 19 '26 |
Buy |
5.71 |
2,094 |
11,950 |
2,439,918 |
| Opaleye Management Inc. | 10% Owner |
Mar 16 '26 |
Buy |
5.78 |
1,331 |
7,696 |
2,435,343 |
| Opaleye Management Inc. | 10% Owner |
Mar 13 '26 |
Buy |
5.75 |
7,358 |
42,286 |
2,434,012 |
| Opaleye Management Inc. | 10% Owner |
Mar 12 '26 |
Buy |
5.85 |
5,708 |
33,416 |
2,426,654 |
| Opaleye Management Inc. | 10% Owner |
Mar 09 '26 |
Buy |
5.85 |
2,179 |
12,742 |
2,420,946 |
| Opaleye Management Inc. | 10% Owner |
Mar 06 '26 |
Buy |
5.80 |
1,900 |
11,018 |
2,418,767 |
| Opaleye Management Inc. | 10% Owner |
Mar 05 '26 |
Buy |
5.80 |
47,023 |
272,621 |
2,416,867 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Buy |
5.81 |
19,795 |
115,001 |
2,374,844 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Buy |
5.75 |
51,411 |
295,624 |
2,355,049 |
| Opaleye Management Inc. | 10% Owner |
Mar 02 '26 |
Buy |
5.80 |
20,000 |
116,000 |
2,308,638 |
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):